Maravai LifeSciences (NASDAQ:MRVI) PT Lowered to $7.00 at The Goldman Sachs Group
Maravai LifeSciences (NASDAQ:MRVI – Free Report) had its target price trimmed by The Goldman Sachs Group from $8.00 to $7.00 in a report issued on Tuesday morning, Benzinga reports. The brokerage currently has a neutral rating on the stock. A number of other research firms have also recently commented on MRVI. Robert W. Baird upped […]
More Stories
Hegseth, Rubio Brief Lawmakers on US Operation in Venezuela
By Joseph Lord and Nathan Worcester WASHINGTON—Secretary of War Pete Hegseth and Secretary of State Marco Rubio on Monday briefed...
Ford Reports Best Annual US Vehicle Sales in 8 Years as Hybrids, Trucks Offset EV Slowdown
By Tom Ozimek Ford Motor Company on Jan. 6 reported its strongest annual U.S. vehicle sales since 2019, buoyed by...
Trucking Insiders Reveal How Licensing System Enabled Illegal Immigrant Drivers
By Jacob Burg When a semi-truck driver made an illegal U-turn on the Florida Turnpike in August 2025, causing the...
Venezuelan Opposition Leader Machado Hails Trump for Capture of Maduro
By Kimberly Hayek Venezuelan opposition leader Maria Corina Machado celebrated President Donald Trump for making the decision to capture Nicolás...
Morgan Stanley Lifts Gold Forecast to $4,800, Citing Fed Cuts and Global Risk
By Tom Ozimek Gold prices are poised to climb to fresh record highs by the end of the year, with...
Key Takeaways From Maduro’s First Court Appearance
By Arjun Singh and Sam Dorman NEW YORK CITY—Deposed Venezuelan leader Nicolás Maduro and his wife, Cilia Flores, made their...